Találati lista | Tudóstér

001-es BibID:	BIBFORM033529
035-os BibID:	PMID:19147617
Első szerző:	Kowal-Bielecka, Otylia
Cím:	EULAR recommendations for the treatment of systemic sclerosis : a report from the EULAR Scleroderma Trials and Research group (EUSTAR) / O. Kowal-Bielecka, R. Landewé, J. Avouac, S. Chwiesko, I. Miniati, L. Czirjak, P. Clements, C. Denton, D. Farge, K. Fligelstone, I. Földvari, D. E. Furst, U. Müller-Ladner, J. Seibold, R. M. Silver, K. Takehara, B. Garay Toth, A. Tyndall, G. Valentini, F. van den Hoogen, F. Wigley, F. Zulian, Marco Matucci-Cerinic, EUSTAR co-authors
Dátum:	2009
ISSN:	0003-4967
Megjegyzések:	PURPOSE: The optimal treatment of systemic sclerosis (SSc) is a challenge because the pathogenesis of SSc is unclear and it is an uncommon and clinically heterogeneous disease affecting multiple organ systems. The aim of the European League Against Rheumatism (EULAR) Scleroderma Trials and Research group (EUSTAR) was to develop evidence-based, consensus-derived recommendations for the treatment of SSc. METHODS: To obtain and maintain a high level of intrinsic quality and comparability of this approach, EULAR standard operating procedures were followed. The task force comprised 18 SSc experts from Europe, the USA and Japan, two SSc patients and three fellows for literature research. The preliminary set of research questions concerning SSc treatment was provided by 74 EUSTAR centres. RESULTS: Based on discussion of the clinical research evidence from published literature, and combining this with current expert opinion and clinical experience, 14 recommendations for the treatment of SSc were formulated. The final set includes the following recommendations: three on SSc-related digital vasculopathy (Raynaud's phenomenon and ulcers); four on SSc-related pulmonary arterial hypertension; three on SSc-related gastrointestinal involvement; two on scleroderma renal crisis; one on SSc-related interstitial lung disease and one on skin involvement. Experts also formulated several questions for a future research agenda. CONCLUSIONS: Evidence-based, consensus-derived recommendations are useful for rheumatologists to help guide treatment for patients with SSc. These recommendations may also help to define directions for future clinical research in SSc.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Annals Of The Rheumatic Diseases. - 68 : 5 (2009), p. 620-628. -
További szerzők:	Landewé, Robert Avouac, Jérôme Chwiesko, S. Miniati, I. Czirják László Clements, Philip Denton, Christopher Farge, D. Fligelstone, Kim Földvári I. Furst, Daniel E. Müller-Ladner, Ulf Seibold, J. Silver, R. M. Takehara, Kazuhiro Garay Tóth B. Tyndall, Alan Valentini, Gabriele Hoogen, F. van den Wigley, Frederic Zulian, Francesco Matucci-Cerinic, Marco Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) EUSTAR
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM084878
Első szerző:	Oláh Csaba (idegsebész)
Cím:	Cognitive dysfunction in autoimmune rheumatic diseases / Oláh Csaba, Schwartz Noa, Denton Christopher, Kardos Zsófia, Putterman Chaim, Szekanecz Zoltán
Dátum:	2020
ISSN:	1478-6354 1478-6362
Megjegyzések:	For people with chronic autoimmune rheumatic diseases (AIRD), such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or systemic sclerosis (SSc), normal cognitive functions are essential for performing daily activities. These diseases may be associated with cognitive dysfunction (CD). In RA, CD has been associated with age, lower education and disease duration and activity. Great advances have been achieved in neuropsychiatric SLE in the identification of pathogenic pathways, assessment and possible treatment strategies. SSc rarely exerts direct effects on the brain and cognitive function. However, the psychological burden that includes depression, anxiety and social impact may be high. AIRD patients with sustained disease activity, organ damage or lower education should be evaluated for CD. The control of systemic inflammation together with tailored behavioural cognitive therapies may benefit these patients.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Cognitive function Cognitive dysfunction Rheumatoid arthritis Systemic lupus erythematosus Neuropsychiatric lupus Systemic sclerosis
Megjelenés:	Arthritis Research & Therapy. - 22 : 1 (2020), p. 1-7. -
További szerzők:	Schwartz, Noa Denton, Christopher Kardos Zsófia Putterman, Chaim Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Pályázati támogatás:	TAMOP-4.2.4.A/2-11/1-2012-0001 TÁMOP GINOP-2.3.2-15-2016-00015 GINOP GINOP-2.3.2-15-2016-00050 GINOP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: